Aplastic anemia.

Seiji Kojima; Norbert Frickhofen; H Joachim Deeg; Shinichiro Okamoto; Judith Marsh; Masanao Teramura; Andrea Bacigalupo; Hideaki Mizoguchi

doi:10.1532/ijh97.05138

PubMed · 16533743

Aplastic anemia.

Seiji Kojima·Norbert Frickhofen·H Joachim Deeg·Shinichiro Okamoto·Judith Marsh·Masanao Teramura·Andrea Bacigalupo·Hideaki Mizoguchi

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Anemia, Aplastic Hematopoietic Stem Cells Humans Immunosuppression Therapy Mesenchymal Stem Cells Pancytopenia T-Lymphocytes Consensus Statement Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Seiji Kojima, Norbert Frickhofen, H Joachim Deeg, Shinichiro Okamoto, Judith Marsh, Masanao Teramura, Andrea Bacigalupo, Hideaki Mizoguchi. 2005. Aplastic anemia.. https://doi.org/10.1532/ijh97.05138

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Remission of aplastic anemia induced by treatment for Graves disease in a pediatric patient.

Aplastic anemia (AA) is mediated by T-cell autoimmunity in the majority of cases; it is rare and mostly idiopathic in children. We describe a child, who developed AA following Graves' disease which could not be attributed to antithyroid drugs. We hypothesized that both diseases were caused by similar autoimmune process. We monitored the blood counts and did not administer any conventional treatment for AA assuming that the existing anti- hematopoietic stem cell humoral and cellular immunity might subside with induction of remission of Grave's disease. The child went into complete remission with the treatment of the Graves' disease.

Anemia, Aplastic↗

PubMed2007

Immunotherapy for severe aplastic anemia following orthotopic liver transplantation in children.

Severe aplastic anemia is a well-recognized complication of fulminant non-A, non-B, and non-C hepatitis requiring orthotopic liver transplantation. The first line of therapy for cure in the treatment of aplastic anemia is a histocompatible bone marrow transplant. Immunosuppressive therapy is also effective if a histocompatible donor is not available. We describe two children who developed severe aplastic anemia following orthotopic liver transplant who achieved bone marrow recovery with a single course of anti-thymocyte globulin, solumedrol, and adjustments to their immunosuppressive therapy for prevention of liver allograft rejection.

Anemia, Aplastic↗

PubMed2007

Acquired immune cytopenias post-cardiac transplantation respond to rituximab.

Hematologic abnormalities following solid organ transplantation are infrequently autoimmune in origin. We present a series of autoimmune cytopenias developing as a late complication of pediatric cardiac transplantation. Autoimmune cytopenias represented include autoimmune hemolytic anemia, acquired Glanzmann thrombasthenia, and idiopathic thrombocytopenic purpura. Standard therapies were used in each patient without sustainable results. Eventually, each patient was treated with and responded to rituximab. In this report, we review these cases, propose potential mechanisms for development of autoimmune cytopenias, and discuss our experience with rituximab in managing refractory autoimmune cytopenias.

Anemia, Aplastic↗